Ari Maizel
Executive Vice President and Head of Commercial
Other
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $530,000 | $3,188,657 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $510,000 | $3,198,507 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $445,000 | $3,920,771 |
Earnings-call appearances
-
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 102026-08-10
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q4 FY2025 Earnings Call2026-02-23
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q3 FY2025 Earnings Call2025-11-03
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q2 FY2025 Earnings Call2025-08-04
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q1 FY2025 Earnings Call2025-05-05
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q4 FY2024 Earnings Call2025-02-18
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q3 FY2024 Earnings Call2024-11-12
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q2 FY2024 Earnings Call2024-08-05
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q1 FY2024 Earnings Call2024-05-06
Axsome Therapeutics, Inc. (AXSM)
-
Axsome Therapeutics, Inc. Q4 FY2023 Earnings Call2024-02-20
Axsome Therapeutics, Inc. (AXSM)